UroGen Pharma Ltd.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $8.2M | $17.5M |
| Cost of Revenue | $600.0K | $28.0K |
| Gross Profit | $7.6M | $17.5M |
| Gross Margin | 92.6% | 99.8% |
| Operating Expenses | ||
| Research & Development | $18.7M | — |
| SG&A Expense | $8.8M | $6.4M |
| Operating Income | $-20.0M | $798.0K |
| Operating Margin | -244.5% | 4.6% |
| Interest Expense | — | — |
| Pretax Income | $-20.0M | $-1.9M |
| Income Tax Expense | $19.0K | — |
| Net Income | $-20.0M | $-1.9M |
| Net Margin | -245.2% | -11.1% |
| EPS (Basic) | $-2.14 | $-1.91 |
| EPS (Diluted) | $-2.14 | $-1.91 |
| Shares Outstanding (Basic) | 13.8M | — |
| Shares Outstanding (Diluted) | 13.8M | — |
| Dividends Per Share | — | — |